[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341353-105":3,"detail-sidebar-cat-0-en-105":73,"doc-detail-341353-en":122},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":66,"head_meta":68,"extra_data":70,"updated_unix":72},105,"en","targeting-the-glutamine-metabolism-to-suppress-cell-proliferation-in-mesenchymal-docetaxel-resistant-prostate-cancer","Targeting the glutamine metabolism to suppress cell proliferation in mesenchymal docetaxel-resistant prostate cancer","","Docetaxel-resistant metastatic prostate cancer is linked to a mesenchymal phenotype with metabolic rewiring toward oxidative phosphorylation driven largely by glutamine. Glutamine deprivation was tested in docetaxel-sensitive and -resistant cell models, showing that resistant sub-lines are vulnerable. Mechanistically, deprivation reduced OXPHOS and ATP, disrupting cell-cycle progression. Genetic and chemical inhibition of GLS1 confirmed glutamine-metabolism dependency and identified a high-GLS1 subgroup after docetaxel failure with poorer survival, supporting GLS1 inhibition as a targeted therapeutic rationale.",{"@graph":14,"@context":65},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/targeting-the-glutamine-metabolism-to-suppress-cell-proliferation-in-mesenchymal-docetaxel-resistant-prostate-cancer/341353/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/targeting-the-glutamine-metabolism-to-suppress-cell-proliferation-in-mesenchymal-docetaxel-resistant-prostate-cancer/341353.png","ImageObject",300,407,{"name":42,"@type":43},"Aria","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59],{"name":60,"@type":61,"acceptedAnswer":62},"Why is GLS1 considered a potential therapeutic target?","Question",{"text":63,"@type":64},"Both genetic and chemical inhibition of GLS1 validate that glutamine-metabolism dependency underlies the glutamine deprivation effects, supporting targeted GLS1 inhibition.","Answer","https://schema.org",{"og:url":32,"og:type":67,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":69,"canonical":32},"index,follow",{"doc_id":71,"site_id":7},341353,1790187349,{"code":4,"msg":74,"data":75},"success",[76,80,84,88,93,98,103,107,112,115,118],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":77,"show_sort_weight":78,"slug":79},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":81,"show_sort_weight":82,"slug":83},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Exam",70,"exam",{"id":89,"doc_module":4,"doc_module_name":25,"category_name":90,"show_sort_weight":91,"slug":92},5,"Comic",60,"comic",{"id":94,"doc_module":4,"doc_module_name":25,"category_name":95,"show_sort_weight":96,"slug":97},6,"Technology",50,"technology",{"id":99,"doc_module":4,"doc_module_name":25,"category_name":100,"show_sort_weight":101,"slug":102},7,"Healthcare",40,"healthcare",{"id":104,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":105,"slug":106},8,30,"research-report",{"id":108,"doc_module":4,"doc_module_name":25,"category_name":109,"show_sort_weight":110,"slug":111},9,"Religion & Spirituality",20,"religion-spirituality",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":113,"show_sort_weight":110,"slug":114},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":55,"slug":117},"Lifestyle","lifestyle",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":89,"slug":121},19,"General","general",{"code":4,"msg":74,"data":123},{"doc_id":71,"user_id":124,"nickname":42,"user_avatar":125,"doc_module":4,"category_id":104,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":131,"language":132,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":12,"update_tm":136,"read_time":137,"preview_page_count":33,"preview_urls":138},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","[www.nature.com/onc](www.nature.com/onc Oncogene)[ Oncogene](www.nature.com/onc Oncogene)  \nARTICLE OPEN   \nTargeting the glutamine metabolism to suppress cell proliferation in mesenchymal docetaxel-resistant prostate cancer  \nAlicia-Marie K. Beier 1, Celina Ebersbach 1, Tiziana Siciliano 1, Jana Scholze1, Jörg Hofmann 1, Pia Hönscheid 2,3, Gustavo B. Baretton2,3, Kevin Woods4,5, Borhane Guezguez4,5, Anna Dubrovska 6,7,8,9, Sascha D. Markowitsch 10, Christian Thomas1,3, Martin Puhr 11 and Holger H. H. Erb 1 ✉  \n© The Author(s) 2024  \n\n|  | Docetaxel (DX) serves as a palliative treatment option for metastatic prostate cancer (PCa) . Despite initial remission, acquired DX resistance is inevitable. The mechanisms behind DX resistance have not yet been deciphered, but a mesenchymal phenotype is associated with DX resistance. Mesenchymal phenotypes have been linked to metabolic rewiring, obtaining most ATP production by oxidative phosphorylation (OXPHOS) powered substantially by glutamine (Gln) . Likewise, Gln is known to play an essential role in modulating bioenergetic, redox homeostasis and autophagy. Herein, investigations of Gln deprivation on DX-sensitive and\u003Cbr>-resistant (DR) PCa cells revealed that the DR cell sub-lines were susceptible to Gln deprivation. Mechanistically, Gln deprivation reduced OXPHOS and ATP levels, causing a disturbance in cell cycle progression. Genetic and chemical inhibition of the Glnmetabolism key protein GLS1 could validate the Gln deprivation results, thereby representing a valid therapeutic target. Moreover, immunohistological investigation of GLS1 revealed a high-expressing GLS1 subgroup post-docetaxel failure, exhibiting low overall survival. This subgroup presents an intriguing opportunity for targeted therapy focusing on glutamine metabolism. Thus, these ﬁndings highlight a possible clinical rationale for the chemical inhibition of GLS1 as a therapeutic strategy to target mesenchymal |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| DR PCa cells, thereby delaying accelerated tumour progression. |  |  |\n|  | Oncogene (2024) 43:2038–2050; [https://doi.org/10.1038/s41388-024-03059-4](https://doi.org/10.1038/s41388-024-03059-4) |  |\n|  |  |  |\n\nINTRODUCTION  \nDocetaxel (DX) is a widely used chemotherapy drug in cancer treatment, including metastatic prostate cancer (PCa), the second most common cancer in men and the ﬁfth leading cause of cancer-related death in men worldwide [1–4] . In castrationresistant prostate cancer (CRPC), docetaxel treatment signiﬁcantly increased overall survival, reduced pain, decreased prostatespeciﬁc antigen serum levels, and enhanced quality of life. However, approximately 40–45% of patients with metastatic (m) CRPC do not respond to docetaxel (DX) or develop therapy resistance [5, 6]. Therefore, new therapeutic strategies are required to develop new and more effective treatments to improve docetaxel and treat docetaxel-resistant (DR) mCRPC.  \nSeveral mechanisms of docetaxel resistance have been identiﬁed, including increased drug efﬂux, drug-binding site mutations in microtubules, and increased anti-apoptotic and pro-survival pathways [7, 8] . Moreover, in vitro and  \nimmunohistological studies demonstrated that docetaxelresistant mCRPC has an increased population of cells with amesenchymal phenotype [9] . Moreover, patients with tumour relapse after docetaxel treatment have signiﬁcantly reduced E-cadherin expression, indicating an elevated mesenchymal cell sub-population [9] .  \nMesenchymal cancer cells have already been linked to altered invasion and motility properties and seem to adopt a cancer stem cell (CSC)-like phenotype and consequently increased tumourforming potential [9–11]. Due to these adaptations, distinct energy requirements are needed, resulting in the reprogramming of metabolism to prioritise energy production by increased oxidative phosphorylation (OXPHOS), glu","cbCais3G8Ied29RG","https://ap.wps.com/l/cbCais3G8Ied29RG","pdf",5556183,13,"English","# Introduction\n# Glutamine metabolism as a driver of docetaxel resistance\n# Mechanistic impact of glutamine deprivation on resistant cells\n# GLS1 inhibition as a therapeutic strategy\n# Clinical relevance of GLS1 expression and survival","[{\"question\":\"Why is GLS1 considered a potential therapeutic target?\",\"answer\":\"Both genetic and chemical inhibition of GLS1 validate that glutamine-metabolism dependency underlies the glutamine deprivation effects, supporting targeted GLS1 inhibition.\"}]","Targeting the glutamine metabolism to suppress cell proliferation in mesenchymal docetaxel-resistant prostate cancer | PDF",1790041636,33,[139,143,147,151],{"page_no":22,"url":140,"width":141,"height":142},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7bd4a3d9b37a034284e57c24e31801d.webp",983,1305,{"page_no":26,"url":144,"width":145,"height":146},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2eac82f35ae0a42de5f4fbf304c61aac.webp",982,1304,{"page_no":30,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4bce02b4624f97d7eac208169d3b6930.webp",981,1303,{"page_no":33,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/99278df6820b6d0deec8d5223f754b73.webp",980,1301]